Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Accounts Payables (2016 - 2020)

Historic Accounts Payables for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $542068.0.

  • Monopar Therapeutics' Accounts Payables rose 1207.49% to $542068.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $542068.0, marking a year-over-year increase of 1207.49%. This contributed to the annual value of $724165.0 for FY2019, which is 8124.47% up from last year.
  • According to the latest figures from Q3 2020, Monopar Therapeutics' Accounts Payables is $542068.0, which was up 1207.49% from $525748.0 recorded in Q2 2020.
  • Monopar Therapeutics' 5-year Accounts Payables high stood at $724165.0 for Q4 2019, and its period low was $64510.0 during Q4 2016.
  • Moreover, its 5-year median value for Accounts Payables was $443520.0 (2020), whereas its average is $420685.1.
  • In the last 5 years, Monopar Therapeutics' Accounts Payables skyrocketed by 38343.98% in 2017 and then tumbled by 2352.92% in 2020.
  • Quarter analysis of 5 years shows Monopar Therapeutics' Accounts Payables stood at $64510.0 in 2016, then skyrocketed by 383.44% to $311867.0 in 2017, then grew by 28.12% to $399551.0 in 2018, then surged by 81.24% to $724165.0 in 2019, then dropped by 25.15% to $542068.0 in 2020.
  • Its Accounts Payables stands at $542068.0 for Q3 2020, versus $525748.0 for Q2 2020 and $443520.0 for Q1 2020.